TY - JOUR
T1 - Relationship of coffee consumption with a decline in kidney function among patients with type 2 diabetes
T2 - The Fukuoka Diabetes Registry
AU - Komorita, Yuji
AU - Ohkuma, Toshiaki
AU - Iwase, Masanori
AU - Fujii, Hiroki
AU - Ide, Hitoshi
AU - Oku, Yutaro
AU - Higashi, Taiki
AU - Oshiro, Ayaka
AU - Sakamoto, Wakako
AU - Yoshinari, Masahito
AU - Nakamura, Udai
AU - Kitazono, Takanari
N1 - Funding Information:
The authors thank Drs Dongchon Kang, Shinako Ogata‐Kaizu, Yoichiro Hirakawa, Tamaki Jodai‐Kitamura, Ai Murao‐Kimura (Kyushu University), Satoshi Sasaki (University of Tokyo), Nobuhiro Sasaki (Fukuoka Red Cross Hospital), Kiyohide Nunoi, Yuichi Sato (St. Mary’s Hospital), Daisuke Gotoh (Kyushu Central Hospital), Sakae Nohara (Fukuoka Higashi Medical Center), Masae Minami (Clinic Minami Masae), Miya Wada (Wada Miya Naika Clinic), Yoshifumi Yokomizo (Yokomizo Naika Clinic), Masanori Kikuchi, Yohei Kikuchi (Kikuchi Naika Clinic), Riku Nomiyama (Suzuki Naika Clinic), Shin Nakamura (Nakamura Naika Clinic), Kenji Tashiro (Oshima Eye Hospital), Mototaka Yoshinari (Yoshinari Naika Clinic), Kojiro Ichikawa (Fukutsu Naika Clinic) and Yutaka Kiyohara (Hisayama Research Institute for Lifestyle Diseases). The authors also thank the clinical research coordinators Chiho Ohba (Hisayama Research Institute for Lifestyle Diseases), Yuka Kawakami, and Yoko Nishioka (Kyushu University), and the following members of the administration office: Tomoko Matake (Hisayama Research Institute for Lifestyle Diseases), Junko Ishimatsu, and Mitsuko Kojima (Kyushu University). In addition, we thank Edanz ( https://jp.edanz.com/ac ) for editing drafts of this manuscript. This work was supported by The Japan Society for the Promotion of Science KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant numbers 20K19663 to YK, 19K24229 and 21K11700 to TO, 23249037 and 23659353 to MI, and 16K00861 to HF), the Honjo International Scholarship Foundation (to YK), the All‐Japan Coffee Association (to YK), the Nakatomi Foundation (to YK), a Junior Scientist Development Grant of the Japan Diabetes Society (to YK and TO), the Lilly Research Grant Program for Bone & Mineral Research from the Japan Osteoporosis Foundation (to YK), a grant from the Clinical Research Promotion Foundation (to YK), the Kondou Kinen Medical Foundation Medical Research Encouragement Prize (to YK), and grants for young researchers from the Japan Association for Diabetes Education and Care (to TO).
Funding Information:
The authors thank Drs Dongchon Kang, Shinako Ogata-Kaizu, Yoichiro Hirakawa, Tamaki Jodai-Kitamura, Ai Murao-Kimura (Kyushu University), Satoshi Sasaki (University of Tokyo), Nobuhiro Sasaki (Fukuoka Red Cross Hospital), Kiyohide Nunoi, Yuichi Sato (St. Mary’s Hospital), Daisuke Gotoh (Kyushu Central Hospital), Sakae Nohara (Fukuoka Higashi Medical Center), Masae Minami (Clinic Minami Masae), Miya Wada (Wada Miya Naika Clinic), Yoshifumi Yokomizo (Yokomizo Naika Clinic), Masanori Kikuchi, Yohei Kikuchi (Kikuchi Naika Clinic), Riku Nomiyama (Suzuki Naika Clinic), Shin Nakamura (Nakamura Naika Clinic), Kenji Tashiro (Oshima Eye Hospital), Mototaka Yoshinari (Yoshinari Naika Clinic), Kojiro Ichikawa (Fukutsu Naika Clinic) and Yutaka Kiyohara (Hisayama Research Institute for Lifestyle Diseases). The authors also thank the clinical research coordinators Chiho Ohba (Hisayama Research Institute for Lifestyle Diseases), Yuka Kawakami, and Yoko Nishioka (Kyushu University), and the following members of the administration office: Tomoko Matake (Hisayama Research Institute for Lifestyle Diseases), Junko Ishimatsu, and Mitsuko Kojima (Kyushu University). In addition, we thank Edanz (https://jp.edanz.com/ac) for editing drafts of this manuscript. This work was supported by The Japan Society for the Promotion of Science KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant numbers 20K19663 to YK, 19K24229 and 21K11700 to TO, 23249037 and 23659353 to MI, and 16K00861 to HF), the Honjo International Scholarship Foundation (to YK), the All-Japan Coffee Association (to YK), the Nakatomi Foundation (to YK), a Junior Scientist Development Grant of the Japan Diabetes Society (to YK and TO), the Lilly Research Grant Program for Bone & Mineral Research from the Japan Osteoporosis Foundation (to YK), a grant from the Clinical Research Promotion Foundation (to YK), the Kondou Kinen Medical Foundation Medical Research Encouragement Prize (to YK), and grants for young researchers from the Japan Association for Diabetes Education and Care (to TO).
Publisher Copyright:
© 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
PY - 2022/6
Y1 - 2022/6
N2 - Aims/Introduction: The evidence regarding the effects of coffee consumption on incident chronic kidney disease is inconclusive, and no studies have investigated the relationship in patients with diabetes. We aimed to prospectively investigate the relationship between coffee consumption and the decline in estimated glomerular function rate (eGFR) in patients with type 2 diabetes. Materials and Methods: A total of 3,805 patients (2,112 men, 1,693 women) with type 2 diabetes (mean age 64.2 years) and eGFR ≥60 mL/min/1.73 m2 were followed (completion of follow up, 97.6%; median 5.3 years). Coffee consumption was assessed at baseline. The end-point was a decline in eGFR to <60 mL/min/1.73 m2 during the follow-up period. Results: During follow up, 840 participants experienced a decline in eGFR to <60 mL/min/1.73 m2. Higher coffee consumption reduced the risk of decline in eGFR. Compared with no coffee consumption, the multivariate-adjusted hazard ratios (95% confidence intervals) were 0.77 (0.63–0.93) for less than one cup per day, 0.77 (0.62–0.95) for one cup per day and 0.75 (0.62–0.91) for two or more cups per day (P for trend 0.01). This trend was unaffected by further adjustment for baseline eGFR and albuminuria. The mean eGFR change per year was −2.16 mL/min/1.73 m2 with no coffee consumption, −1.89 mL/min/1.73 m2 with less than one cup per day, −1.80 mL/min/1.73 m2 with one cup per day and −1.78 mL/min/1.73 m2 with two or more cups per day (P for trend 0.03). Conclusions: Coffee consumption is significantly associated with a lower risk of decline in eGFR in patients with type 2 diabetes.
AB - Aims/Introduction: The evidence regarding the effects of coffee consumption on incident chronic kidney disease is inconclusive, and no studies have investigated the relationship in patients with diabetes. We aimed to prospectively investigate the relationship between coffee consumption and the decline in estimated glomerular function rate (eGFR) in patients with type 2 diabetes. Materials and Methods: A total of 3,805 patients (2,112 men, 1,693 women) with type 2 diabetes (mean age 64.2 years) and eGFR ≥60 mL/min/1.73 m2 were followed (completion of follow up, 97.6%; median 5.3 years). Coffee consumption was assessed at baseline. The end-point was a decline in eGFR to <60 mL/min/1.73 m2 during the follow-up period. Results: During follow up, 840 participants experienced a decline in eGFR to <60 mL/min/1.73 m2. Higher coffee consumption reduced the risk of decline in eGFR. Compared with no coffee consumption, the multivariate-adjusted hazard ratios (95% confidence intervals) were 0.77 (0.63–0.93) for less than one cup per day, 0.77 (0.62–0.95) for one cup per day and 0.75 (0.62–0.91) for two or more cups per day (P for trend 0.01). This trend was unaffected by further adjustment for baseline eGFR and albuminuria. The mean eGFR change per year was −2.16 mL/min/1.73 m2 with no coffee consumption, −1.89 mL/min/1.73 m2 with less than one cup per day, −1.80 mL/min/1.73 m2 with one cup per day and −1.78 mL/min/1.73 m2 with two or more cups per day (P for trend 0.03). Conclusions: Coffee consumption is significantly associated with a lower risk of decline in eGFR in patients with type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85125047706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125047706&partnerID=8YFLogxK
U2 - 10.1111/jdi.13769
DO - 10.1111/jdi.13769
M3 - Article
C2 - 35152568
AN - SCOPUS:85125047706
VL - 13
SP - 1030
EP - 1038
JO - Journal of Diabetes Investigation
JF - Journal of Diabetes Investigation
SN - 2040-1116
IS - 6
ER -